Sponsors

How to use real-world data without overpromising in trial planning

A practical guide for sponsors using real-world data to improve clinical trial feasibility, recruitment planning, and protocol design without creating false confidence.

Real-world data can improve feasibility planning, but it should be paired with site feedback, patient burden review, and early recruitment metrics before teams make enrollment assumptions.

In this guide

Key points

  • Real-world data can help pressure-test eligibility, geography, routine care patterns, and screening assumptions.
  • Database counts do not prove patients are reachable, interested, eligible, or near a capable site.
  • Sponsors should combine real-world data with site feedback, records-readiness planning, and early funnel evidence.

Real-world data can help, but it is not magic

FDA describes real-world data as data relating to patient health status or healthcare delivery collected from sources such as electronic health records, claims, registries, and digital health technologies.

Used carefully, real-world data can improve feasibility planning. Used carelessly, it can create false confidence before a study ever opens.

Where real-world data can help

Real-world data can support early planning questions: how common key eligibility criteria appear in routine care, which geographic areas may have more relevant patient populations, what comorbidities or medication patterns may affect eligibility, and how often patients receive tests needed for screening.

It can also reveal whether a protocol depends on procedures that are routine in some settings but unusual in others. That matters because a patient who exists in a database may still be difficult to screen if records, labs, or site access are not practical.

Where it can mislead

Real-world data may be incomplete, inconsistent, or collected for billing and care rather than research. A database may show that patients exist, but not that they are reachable, interested, eligible, or near a capable site.

A better approach pairs real-world data with site feedback, patient burden review, and operational screening metrics. That combination helps teams distinguish theoretical prevalence from recruitable opportunity.

Use a tactical workflow

Start with the protocol's must-have criteria, pressure-test those criteria against real-world data, ask sites which criteria will create screening friction, review whether required procedures are routine or unusual, and use early recruitment data to adjust outreach and site support.

For example, a sponsor may estimate strong eligibility using claims data. After launch, sites may report that many patients lack a required recent lab result. The rescue plan is not simply more advertising. It is workflow repair: clarify lab windows, support record collection, and adjust prescreening language.

Where TrialsNest fits

TrialsNest can help connect planning assumptions to what happens after launch: source quality, prescreening status, records blockers, scheduling movement, screen failures, and close reasons.

That gives sponsors a way to compare real-world planning assumptions against actual site workflow evidence.

Sources used for this playbook

FDA Real-World Evidence: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

FDA Framework for Real-World Evidence Program: https://www.fda.gov/media/120060/download

Sources and editorial notes

Published .

This guide explains recruitment work and questions to discuss with your team.

This information is educational. Your study team makes medical, eligibility, and enrollment decisions.

See TrialsNest in action

Bring this workflow into one place.

Manage inquiries, follow-ups, records, and visits. Keep sponsors updated on progress.

Aggregate study reporting

Sponsor portfolio

6 active studies482 inquiries18 research sites
Study APhase IIb

39 / 50 enrolled78%

Study BPhase III

74 / 120 enrolled62%

Study CPhase I

9 / 10 enrolled90%

Keep reading